BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11016641)

  • 1. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.
    Kilic T; Alberta JA; Zdunek PR; Acar M; Iannarelli P; O'Reilly T; Buchdunger E; Black PM; Stiles CD
    Cancer Res; 2000 Sep; 60(18):5143-50. PubMed ID: 11016641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
    Geng L; Shinohara ET; Kim D; Tan J; Osusky K; Shyr Y; Hallahan DE
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):263-71. PubMed ID: 16274936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
    Shawver LK; Schwartz DP; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs JS; Tang C; Ullrich A; Berens ME; Hersh E; McMahon G; Hirth KP; Powell TJ
    Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
    Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker BJ; Lydon NB
    Cancer Res; 1996 Jan; 56(1):100-4. PubMed ID: 8548747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
    Sjöblom T; Shimizu A; O'Brien KP; Pietras K; Dal Cin P; Buchdunger E; Dumanski JP; Ostman A; Heldin CH
    Cancer Res; 2001 Aug; 61(15):5778-83. PubMed ID: 11479215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
    Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
    Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
    Holdhoff M; Kreuzer KA; Appelt C; Scholz R; Na IK; Hildebrandt B; Riess H; Jordan A; Schmidt CA; Van Etten RA; Dörken B; le Coutre P
    Blood Cells Mol Dis; 2005; 34(2):181-5. PubMed ID: 15727903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
    Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice.
    Blaskovich MA; Lin Q; Delarue FL; Sun J; Park HS; Coppola D; Hamilton AD; Sebti SM
    Nat Biotechnol; 2000 Oct; 18(10):1065-70. PubMed ID: 11017044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.
    Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul M
    Clin Cancer Res; 2001 Mar; 7(3):634-40. PubMed ID: 11297259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
    Attoub S; Rivat C; Rodrigues S; Van Bocxlaer S; Bedin M; Bruyneel E; Louvet C; Kornprobst M; André T; Mareel M; Mester J; Gespach C
    Cancer Res; 2002 Sep; 62(17):4879-83. PubMed ID: 12208734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
    Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
    Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
    Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
    George D
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
    Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ
    Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures.
    Hägerstrand D; Hesselager G; Achterberg S; Wickenberg Bolin U; Kowanetz M; Kastemar M; Heldin CH; Isaksson A; Nistér M; Ostman A
    Oncogene; 2006 Aug; 25(35):4913-22. PubMed ID: 16547494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet-derived growth factor A-chain synthetic peptide inhibits human glioma xenograft proliferation in nude mice.
    Khachigian LM; Field SL; Crouch R; Chesterman CN
    Anticancer Res; 1995; 15(2):337-41. PubMed ID: 7763003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
    Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.